AstraZeneca’s Zactima Submission Delayed, Anti-Thrombotic Moves To Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm now expects to make vandetanib submission for non-small cell lung cancer in first half of 2009.
You may also be interested in...
ASCO Abstracts Hold Some Surprises Including Data On AZ’s Vandetanib, Bristol’s Ipilimumab
Despite the lack of innovative drugs highlighted in ASCO's media briefing on its upcoming annual meeting, there is a range of oncology development updates that will be presented - including some surprises
ASCO Abstracts Hold Some Surprises Including Data On AZ’s Vandetanib, Bristol’s Ipilimumab
Despite the lack of innovative drugs highlighted in ASCO's media briefing on its upcoming annual meeting, there is a range of oncology development updates that will be presented - including some surprises
AstraZeneca R&D: Aim Early To Cut Cycle Time, Build Phase II Pipeline
Current R&D strategy emphasizes improvements to R&D processes, like trying to reduce costs and cycle time. Making go/no-go decisions earlier on is also a goal, R&D execs say in an interview. The firm is in a building phase as it makes up for some major Phase III failures in recent years. AstraZeneca's current late-stage pipeline is mostly focused on lifecycle management